Literature DB >> 11959586

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Yun-Kyung Kim1, Hyunjoo Pai, Hoan-Jong Lee, Su-Eun Park, Eun-Hwa Choi, Jungmin Kim, Je-Hak Kim, Eui-Chong Kim.   

Abstract

To determine the epidemiologic features and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, cases of bacteremia caused by these organisms in children were analyzed retrospectively. Among the 157 blood isolates recovered from 1993 to 1998 at the Seoul National University Children's Hospital, the prevalence of ESBL production was 17.9% among the E. coli isolates and 52.9% among the K. pneumoniae isolates. The commonest ESBLs were SHV-2a and TEM-52. A novel ESBL, TEM-88, was identified. Pulsed-field gel electrophoresis analysis of the ESBL-producing organisms showed extensive diversity in clonality. The medical records of 142 episodes were reviewed. The risk factors for bloodstream infection with ESBL-producing organisms were prior hospitalization, prior use of oxyimino-cephalosporins, and admission to an intensive care unit within the previous month. There was no difference in clinical severity between patients infected with ESBL-producing strains (the ESBL group) and those infected with ESBL-nonproducing strains (the non-ESBL group) at the time of presentation. However, the overall fatality rate for the ESBL group was significantly higher than that for the non-ESBL group: 12 of 45 (26.7%) versus 5 of 87 (5.7%) (P = 0.001). In a subset analysis of patients treated with extended-spectrum cephalosporins with or without an aminoglycoside, favorable response rates were significantly higher in the non-ESBL group at the 3rd day (6 of 17 versus 33 of 51; P = 0.035), the 5th day (6 of 17 versus 36 of 50; P < 0.05), and the end of therapy (9 of 17 versus 47 of 50; P < 0.001). In conclusion, the ESBL production of the infecting organisms has a significant impact on the clinical course and survival of pediatric patients with bacteremia caused by E. coli and K. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959586      PMCID: PMC127143          DOI: 10.1128/AAC.46.5.1481-1491.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Evolution of TEM-related extended-spectrum beta-lactamases in Korea.

Authors:  H Pai; H J Lee; E H Choi; J Kim; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea.

Authors:  H Pai; E H Choi; H J Lee; J Y Hong; G A Jacoby
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.

Authors:  H Pai; J Kim; J Kim; J H Lee; K W Choe; N Gotoh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction.

Authors:  J Kim; H J Lee
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

Review 6.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

7.  Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins.

Authors:  A Bauernfeind; G Hörl
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

8.  Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.

Authors:  L K Siu; P L Lu; P R Hsueh; F M Lin; S C Chang; K T Luh; M Ho; C Y Lee
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

9.  Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea.

Authors:  H Pai; S Lyu; J H Lee; J Kim; Y Kwon; J W Kim; K W Choe
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

10.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

View more
  91 in total

1.  Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in pediatric intensive care units.

Authors:  Tsu-Lan Wu; Ju-Hsin Chia; Lin-Hui Su; An-Jing Kuo; Chishih Chu; Cheng-Hsun Chiu
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

2.  High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns.

Authors:  Hyunjoo Pai; Jung Yun Hong; Jeong-Hum Byeon; Yun-Kyung Kim; Hoan-Jong Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patients.

Authors:  A Gündoğdu; Y B Long; M Katouli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-24       Impact factor: 3.267

4.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.

Authors:  L Calatayud; M Arnan; J Liñares; M A Dominguez; C Gudiol; J Carratalà; M Batlle; J M Ribera; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 7.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

8.  Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.

Authors:  Hyunjoo Pai; Mi-Ran Seo; Tae Yeal Choi
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

9.  Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.

Authors:  Ståle Tofteland; Bjørg Haldorsen; Kristin H Dahl; Gunnar S Simonsen; Martin Steinbakk; Timothy R Walsh; Arnfinn Sundsfjord
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

10.  Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae.

Authors:  Hyunjoo Pai; Cheol-In Kang; Jeong-Hum Byeon; Ki-Deok Lee; Wan Beom Park; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.